Drugs / Autologous Bone Marrow Aspirate Concentrate
Autologous Bone Marrow Aspirate Concentrate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01931007 | Aug 2013 → Jan 2016 | osteoarthritis, knee | Mayo Clinic | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06216028 | Sep 2024 → Aug 2026 overdue | osteoarthritis, knee | CELL Technologies Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Bone Marrow Aspirate Concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06216028 ↗ |
| Known as | BMAC | “Bone marrow aspirate concentrate (BMAC) is increasingly used as a regenerative therapy for musculoskeletal pathological conditions despite limited evidence-based support.” PMID 27566242 ↗ Sep 2016 |
| Known as | Bone marrow aspirate concentrate | “Bone marrow aspirate concentrate (BMAC) is increasingly used as a regenerative therapy for musculoskeletal pathological conditions despite limited evidence-based support.” PMID 27566242 ↗ Sep 2016 |
| Route | Other | “The resulting BMAC was combined with platelet-poor plasma for an injection into the arthritic knee” PMID 27566242 ↗ Sep 2016 |